Iterum Therapeutics
ITRM
ITRM was delisted on the 31st of March, 2026.
21 hedge funds and large institutions have $42.3M invested in Iterum Therapeutics in 2018 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 5 closing their positions.
0.19% less ownership
Funds ownership: 3.17% → 2.99% (-0.19%)
13% less funds holding
Funds holding: 24 → 21 (-3)
41% less capital invested
Capital invested by funds: $71.6M → $42.3M (-$29.4M)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
Hound Partners
New York
|
+$170K |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$85.8K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$72.8K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$26.6K |
| 5 |
Morgan Stanley
New York
|
+$14.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCP
Tourbillon Capital Partners
New York
|
-$1.06M |
| 2 |
Millennium Management
New York
|
-$1.05M |
| 3 |
DIM
DC Investments Management
Mclean,
Virginia
|
-$406K |
| 4 |
Franklin Resources
San Mateo,
California
|
-$236K |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$202K |
ITRM Hedge Fund Activity: Q3 2018 in Review
21 of the 4,347 institutional investors tracked by Wall St. Rank reported a position in Iterum Therapeutics (ITRM) for Q3 2018, worth a combined $42.3M — down 41% from $71.6M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ITRM and 2 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 4 added.
The largest buyer was Hound Partners, opening a new position worth an estimated $170K. The largest seller was Tourbillon Capital Partners, exiting entirely with an estimated $1.06M sold.
- 21 institutional investors held Iterum Therapeutics (ITRM) as of Q3 2018, down from 24 in Q2 2018.
- Funds reported $42.3M of Iterum Therapeutics stock for Q3 2018, down 41% quarter-over-quarter.
- 2 funds opened new Iterum Therapeutics positions in Q3 2018 and 5 closed out, a net change of -3 holders.
- The largest Iterum Therapeutics buyer in Q3 2018 was Hound Partners, an estimated $170K added.
- The largest Iterum Therapeutics seller in Q3 2018 was Tourbillon Capital Partners, an estimated $1.06M sold.
Based on aggregated 13F filings for Q3 2018.